# Fermenta Biotech (NSE: FERMENTA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/FERMENTA · Pivot · prices to 21 Oct 2026

Fermenta Biotech (NSE: FERMENTA) closed at ₹460.55 on 21 Oct 2026. With a market capitalisation of ₹1,344 Cr, it ranks 1329th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.

Its return on equity was 21.2% in FY25. Its 52-week range is ₹248.85 (4 May 2026) to ₹582.65 (6 Oct 2026); the last close is 21.0% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹122 Cr (−13.1% year on year) and net profit ₹19 Cr (−44.2%), on a consolidated basis. Promoters held 64.09% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹460.55 |
| Market cap | ₹1,344 Cr |
| ROE | 21.2% (FY25) |
| ROCE | 24.2% (FY25) |
| Debt to equity | 0.3 |
| 52-week high | ₹582.65 (6 Oct 2026) |
| 52-week low | ₹248.85 (4 May 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹122 Cr | −13.1% | ₹19 Cr | −44.2% | ₹6.66 |
| Q3 FY26 | ₹137 Cr | −12.2% | ₹12 Cr | −68.3% | ₹4.36 |
| Q2 FY26 | ₹130 Cr | +37.0% | ₹18 Cr | +62.1% | ₹6.48 |
| Q1 FY26 | ₹136 Cr | +74.4% | ₹22 Cr | — | ₹7.49 |
| Q4 FY25 | ₹140 Cr | +43.7% | ₹33 Cr | — | ₹11.79 |
| Q3 FY25 | ₹156 Cr | +58.1% | ₹38 Cr | +279.3% | ₹12.71 |
| Q2 FY25 | ₹95 Cr | +67.0% | ₹11 Cr | — | ₹3.94 |
| Q1 FY25 | ₹78 Cr | −5.2% | −₹6 Cr | −368.3% | −₹2.01 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹469 Cr | ₹76 Cr |
| FY24 | ₹336 Cr | −₹24 Cr |
| FY23 | ₹350 Cr | −₹54 Cr |
| FY22 | ₹399 Cr | ₹15 Cr |
| FY21 | ₹377 Cr | ₹43 Cr |
| FY20 | ₹293 Cr | ₹60 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 64.09%
- Foreign institutions: 0.13%
- Domestic institutions: 0.04%
- Non-institutions: 33.20%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Amrutanjan Health Care](https://app.pivotnow.in/stock/AMRUTANJAN) | ₹501.00 | ₹1,448 Cr | 25 | — |
| [Jagsonpal Ser](https://app.pivotnow.in/stock/JAGSNPHARM) | ₹217.95 | ₹1,435 Cr | 34.5 | — |
| [Anlon Healthcare](https://app.pivotnow.in/stock/AHCL) | ₹26.92 | ₹1,431 Cr | 44.1 | — |
| [TTK Healthcare](https://app.pivotnow.in/stock/TTKHLTCARE) | ₹1,007.60 | ₹1,424 Cr | 21.7 | — |
| [Shalby](https://app.pivotnow.in/stock/SHALBY) | ₹126.00 | ₹1,361 Cr | 38.9 | — |
| [Kopran](https://app.pivotnow.in/stock/KOPRAN) | ₹279.00 | ₹1,347 Cr | 52.3 | — |

## Questions and answers

### What is the share price of Fermenta Biotech today?

Fermenta Biotech (NSE: FERMENTA) last closed at ₹460.55 on 21 Oct 2026. Its 52-week high is ₹582.65 and its 52-week low is ₹248.85.

### What is the market cap of Fermenta Biotech?

Fermenta Biotech's market capitalisation is ₹1,344 Cr (₹1,344 Cr) at the 19 Oct 2026 close, ranking 1329th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Fermenta Biotech?

Return on equity was 21.2% in FY25 and return on capital employed was 24.2% in FY25 (consolidated figures).

### Is Fermenta Biotech a debt-free company?

No. Fermenta Biotech's debt-to-equity ratio was 0.3 in FY25, with total debt of ₹15 Cr.

### What were Fermenta Biotech's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Fermenta Biotech reported revenue of ₹122 Cr, −13.1% year on year, and net profit of ₹19 Cr, −44.2% year on year.

### What is the shareholding pattern of Fermenta Biotech?

As of 30 Jun 2026: promoters 64.09%, foreign institutions 0.13%, domestic institutions 0.04%, non-institutions 33.20%.

### Who are Fermenta Biotech's competitors?

The listed Pharma & Healthcare companies closest to Fermenta Biotech by market cap are Amrutanjan Health Care, Jagsonpal Ser, Anlon Healthcare, TTK Healthcare, Shalby and Kopran.

### Is Fermenta Biotech a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Fermenta Biotech's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FERMENTA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.